Founded in 1941, Laboratorios Sanfer (“Sanfer”) is the second largest domestic pharmaceutical company in Mexico and amongst the top 8 largest in Latin America. Laboratorios Bussie, S.A. (“Bussie”) and Laboratorio International de Colombia, S.A.S. (“Labinco”) are fully owned subsidiaries of Sanfer and were acquired in 2008 and 2015, respectively. Bussie and Labinco (hereafter referred to as “Sanfer Colombia”) commercialize a wide portfolio of prescription and over-the-counter (OTC) drugs (e.g. pulmonology, ophthalmology, gastrointestinal, cardiovascular, psychoactive, antiparasitic, antibiotics, and veterinary drugs). With exception of veterinary drugs which are produced by three third-party contract manufacturers, the majority of drugs are produced in Bussie’s and Labinco’s manufacturing plants located in Bogota, Colombia. IFC propose financing a $11.5 million for the construction of a new manufacturing plant for finished dosage forms, which will replace the existing operations, to satisfy the new and more stringent regulatory requirements from the National Institute for Drugs and Food Surveillance (INVIMA). The new plant will be located in an industrial area in the city of Bogota, a few blocks from the existing plants https://goo.gl/maps/jDJQN6VqzQBxejQ49. Administrative offices and the quality control laboratory will remain in separate existing locations.
The "Investment Type" was not available at the moment of the snapshot.
|Private Actor 1||Private Actor 1 Role||Private Actor 1 Sector||Relation||Private Actor 2||Private Actor 2 Role||Private Actor 2 Sector|
|-||-||-||-||LABORATORIOS BUSSIE S A||Client||-|
ACCESS TO INFORMATION
You can submit a request for information disclosure at: https://disclosures.ifc.org/#/inquiries
If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.
ACCOUNTABILITY MECHANISM OF IFC/MIGA
The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org